Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment

 
• By Derrick Gingery
  
Closed up finger on keyboard with word CLINICAL TRIALS
The FDA wants investigators to remind outpatients to fill out COVID-19 PRO instruments to avoid missing data. • Source: Shutterstock

More from Clinical Trials

More from R&D